Skip to content
DataLookout
Menu

ELUCIDATENCT05985655

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Trial sites expanded: 15 → 28 locations
  2. Minor Study sites: 13 to 15v8
  3. Minor Study sites: 12 to 13v7
  4. Notable Eligibility criteria expanded, about 2 words
    • Enrollment target: 165 to 230
    • Secondary endpoints: 6 to 7
    v6
  5. Notable Lead sponsor: Exscientia AI Limited to Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.v5 Show 10 more changesShow less
    • Eligibility criteria expanded, about 42 words
    • Primary endpoints: 5 to 3
    • Enrollment target: 170 to 165
    • Study sites: 7 to 12
    • Interventions: GTAEXS617 (Drug) to GTAEXS617 (Drug), SoC (Drug)
    • Secondary endpoints: 3 to 6
    • Study description shortened, about 62 words
    • Study title revised
    • Study arms: 1 to 4
    • Collaborators shortened, about 3 words
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Study sites: 6 to 7v4
  2. Minor Study sites: 2 to 6v3
  3. Minor Study sites: 1 to 2v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 2 years
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Timeframe: Up to 28 days
Phase 2 : Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Timeframe: Up to 2 years

Secondary (7)

Phase 1: ORR as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Maximum Plasma Concentration (Cmax) of GTAEXS617
Time Maximum Plasma Concentration (Tmax) of GTAEXS617
Area under Plasma Concentration Curve From Time Zero to the Last Quantifiable Concentration (AUC0-inf) of GTAEXS617
Duration of Response (DOR)
Show 2 moreShow less
Progression-Free Survival (PFS)
Disease Control Rate (DCR)

Arms and interventions

Phase 1: Dose Escalation MonotherapyExperimental

Participants will receive GTAEXS617 oral tablets in increasing doses.

Phase 1: Dose Escalation Combination TherapyExperimental

Participants will receive GTAEXS617 oral tablets in increasing doses in combination with standard of care (SoC) treatment.

Phase 2: Dose Expansion MonotherapyExperimental

Participants will receive GTAEXS617 oral tablets at Recommended Phase 2 Dose (RP2D).

Phase 2: Dose Expansion Combination TherapyExperimental

Participants will receive GTAEXS617 oral tablets at RP2D in combination with SoC treatment.

Drugs: GTAEXS617, SoC

Sites

28 sites in 3 countries

United States 19, United Kingdom 5, Belgium 4